IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Flushing Profile of Extended-Release Niacin/Laropiprant at Initiation of Therapy in Asian Lipid Clinic Patients
Kush, Debra1; Hu, Da-Yi2; Ye, Ping3; Kim, Hyo-Soo4; Chen, Erluo; Sirah, Waheeda; Sisk, Christine McCrary; Paolini, John F.; Maccubbin, Darbie
关键词Extended-release Niacin Flushing Laropiprant
刊名CARDIOLOGY
2009
DOI10.1159/000228585
114期:3页:192-198
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Cardiac & Cardiovascular Systems
资助者Merck &amp ; Co. Inc., Whitehouse Station, N.J., USA ; Merck &amp ; Co. Inc., Whitehouse Station, N.J., USA
研究领域[WOS]Cardiovascular System & Cardiology
关键词[WOS]NICOTINIC-ACID ; PRIMARY HYPERCHOLESTEROLEMIA ; CORONARY-DISEASE ; NIACIN NIASPAN ; LONG-TERM ; EFFICACY ; DYSLIPIDEMIA ; TOLERABILITY ; CHOLESTEROL ; LOVASTATIN
英文摘要

Objective: Niacin is underutilized due to flushing, which occurs in over 90% of niacin-treated patients. Laropiprant (LRPT) reduces flushing associated with niacin. This study compared flushing with a combination tablet of extended-release (ER) niacin (ERN)/LRPT to niacin ER (N-ER; without LRPT) during the first week of therapy among patients in Asia. Methods: Following a 1-week placebo run-in, 332 patients with dyslipidemia from China, Korea and Singapore were randomized to ERN/LRPT 1 g/20 mg, N-ER 1 g (given as Niaspan (R)) or placebo in a 2: 2: 1 ratio for 1 week. Patient-reported flushing severity was assessed using the Global Flushing Severity Score (GFSS; none/mild = 0-3; moderate = 4-6; severe = 7-9; extreme = 10). Results: Compared with N-ER, the ERN/LRPT group experienced significantly less flushing (p < 0.001), as measured by maximum GFSS categorized as none/mild, moderate, severe or extreme. Overall, 23.8% of patients in the ERN/LRPT group and 50.0% in the N-ER group (p < 0.001), versus 12.1% in the placebo group, had moderate or greater flushing (GFSS >= 4). Except for flushing, which occurred more frequently in the N-ER group, ERN/LRPT had a safety/tolerability profile similar to that of N-ER. Conclusion: ERN/LRPT produced significantly less flushing than N-ER during the initiation of therapy and was generally well tolerated in Asian patients with dyslipidemia. Copyright (C) 2009 S. Karger AG, Basel

语种英语
资助者Merck &amp ; Co. Inc., Whitehouse Station, N.J., USA ; Merck &amp ; Co. Inc., Whitehouse Station, N.J., USA
WOS记录号WOS:000270364900006
Citation statistics
Cited Times:16[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/55036
Collection北京大学第二临床医学院
作者单位1.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
2.Merck & Co Inc, Merck Res Labs, Cardiovasc Dis, Rahway, NJ 07065 USA
3.Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
4.Seoul Natl Univ Hosp, Seoul 110744, South Korea
Recommended Citation
GB/T 7714
Kush, Debra,Hu, Da-Yi,Ye, Ping,et al. Flushing Profile of Extended-Release Niacin/Laropiprant at Initiation of Therapy in Asian Lipid Clinic Patients[J]. CARDIOLOGY,2009,114(3):192-198.
APA Kush, Debra.,Hu, Da-Yi.,Ye, Ping.,Kim, Hyo-Soo.,Chen, Erluo.,...&Maccubbin, Darbie.(2009).Flushing Profile of Extended-Release Niacin/Laropiprant at Initiation of Therapy in Asian Lipid Clinic Patients.CARDIOLOGY,114(3),192-198.
MLA Kush, Debra,et al."Flushing Profile of Extended-Release Niacin/Laropiprant at Initiation of Therapy in Asian Lipid Clinic Patients".CARDIOLOGY 114.3(2009):192-198.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Kush, Debra]'s Articles
[Hu, Da-Yi]'s Articles
[Ye, Ping]'s Articles
百度学术
百度学术Similar articles in
[Kush, Debra]'s Articles
[Hu, Da-Yi]'s Articles
[Ye, Ping]'s Articles
必应学术
必应学术Similar articles in
[Kush, Debra]'s Articles
[Hu, Da-Yi]'s Articles
[Ye, Ping]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.